Podcast
Podcast
The Bioverge Podcast: Developing Targeted Therapies to Address Heart Failure
Drew Titmarsh, Co-Founder and CEO of Dynomics, sits down with Neil to discuss the lack of innovative therapies to treat heart disease, the company’s discovery platform that uses engineered cardiac organoids that function like adult human heart tissue, and how the company is using this to develop precision therapies to address the root causes of heart failure.
Continue Reading >
Podcast
The Bioverge Podcast: Speeding Drug Development by Unlocking the Mechanism of Action of Cancer Therapies
Summary David Li , Co-Founder and CEO of Meliora Therapeutics , sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how the platform technology to uncover the true ...
Continue Reading >
Podcast
The Bioverge Podcast: Enlisting the Viral Immune System in the Fight Against Cancer
Anat Burkovitz, CEO of TrojanBio, sits down with Neil to discuss its AI-drive antibodies platform, how it enlists the viral immune system in the fight against cancer, and why she thinks the technology will broaden the population of patients who will benefit from immunotherapies.
Continue Reading >
Podcast
The Bioverge Podcast: AI Derived Brain Biomarker for Precision Therapies
On the latest episode of The Bioverge Podcast, Amit Etkin, Founder and CEO of Alto Neuroscience, sits down with Neil Littman to discuss the lack of innovation in psychiatric medicines, how Alto has identified AI-derived brain biomarkers, and how that is fueling its pipeline of precision therapies to treat mental health disorders.
Continue Reading >
Podcast
The Bioverge Podcast: Reengineering Healthcare and Medicine with Technology
Vineeta Agarwala, General Partner at Andreessen Horowitz and lead of the firm’s bio and health fund, sits down with Neil to discuss her investment process, how technology is transforming biotech and healthcare, and why she thinks drug development becoming more and more like software development.
Continue Reading >
Podcast
The Bioverge Podcast: Unlocking the Potential of Genetic Medicines
David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.
Continue Reading >
Podcast
The Bioverge Podcast: Making Medicines Affordable For Everyone
Peter Kolchinsky, Founder and Managing Director of RA Capital Management and Founder of the nonprofit No Patient Left Behind, sits down with Neil to discuss his book “The Great American Drug Deal,” policy fights over pricing, and his organization’s efforts to make medicines affordable for all Americans.
Continue Reading >
Podcast
The Bioverge Podcast: Unleashing the Power of Gene Therapy for a Broad Universe of Diseases
Kriya Therapeutics Co-Founder, Chairman, and CEO Shankar Ramaswamy sits down with Neil to discuss how the company is changing the way gene therapies are designed, developed, and manufactured in an effort to cut costs, accelerate the time to market, and expand the reach of gene therapy to a broad universe of disease.
Continue Reading >
Podcast
The Bioverge Podcast: A Bioinformatician Turned Investor Seeks to Transform Drug Development with Technology
Francisco Gimenez, Partner at 8VC, sits down with Neil to discuss how his background in data science and bioinformatics shapes his investment approach and the potential to transform drug development with technology.
Continue Reading >
Podcast
The Bioverge Podcast: A Rockstar Investor Who Backs Transformational Technologies
D.A. Wallach sits down with Neil to discuss his journey from recording artists to venture investors, his co-founding of Time BioVentures, and his vision from transforming biotechnology and healthcare with technology.
Continue Reading >